ATC Group: P02CA03 Albendazole

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of P02CA03 in the ATC hierarchy

Level Code Title
1 P Antiparasitic products, insecticides and repellents
2 P02 Anthelmintics
3 P02C Antinematodal agents
4 P02CA Benzimidazole derivatives
5 P02CA03 Albendazole

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.4 g

Active ingredients in P02CA03

Active Ingredient Description
Albendazole

Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules.

Related product monographs

Title Information Source Document Type  
ALBENZA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Cyprus (CY)

Estonia (EE)

France (FR)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.